GW Readies Cannabis-based Drug for EU Market

GW Pharmaceutical has announced that its U.K. manufacturing facility has received regulatory approval, in advance of its launch of cannabis-based Sativex into the European market. A blast from the past: We caught up with GW a few years ago to discuss the process by which cannabis plants are turned into active ingredients.